Does losartan affect electrolyte levels, such as potassium and sodium?

Does Losartan Affect Electrolytes?

Yes, losartan can affect electrolyte levels, most importantly by increasing serum potassium (hyperkalemia), and less commonly by causing hyponatremia (low sodium).

Primary Electrolyte Effect: Hyperkalemia (Elevated Potassium)

Losartan, as an angiotensin II receptor blocker (ARB), blocks aldosterone secretion, which reduces potassium excretion by the kidneys. Regular monitoring of serum electrolytes and renal function is mandatory when using losartan 1.

Risk Factors for Hyperkalemia with Losartan:

• Renal impairment (eGFR <60 mL/min) 2
• Concurrent use of other potassium-raising medications:
  • Potassium-sparing diuretics (spironolactone, amiloride, triamterene)
  • ACE inhibitors (dual RAAS blockade)
  • Potassium supplements or salt substitutes 3
• Diabetes mellitus 2
• Advanced age 4

Monitoring Protocol:

Check serum potassium and creatinine at baseline, then 1-2 weeks after initiation or dose changes, and periodically thereafter 1. The FDA label specifically warns that coadministration with other potassium-raising agents may result in hyperkalemia and requires monitoring 3.

Management of Hyperkalemia:

• If potassium >5.5 mmol/L: Reduce losartan dose by 50% and monitor closely 4
• If potassium ≥6.0 mmol/L: Stop losartan immediately and treat hyperkalemia 4
• Consider newer potassium binders (patiromer, sodium zirconium cyclosilicate) to allow continuation of RAAS inhibition when clinically indicated 5, 2

Secondary Electrolyte Effect: Hyponatremia (Low Sodium)

While less common than hyperkalemia, losartan can cause hyponatremia, particularly when combined with thiazide diuretics. Case reports document severe hyponatremia (sodium as low as 99-123 mEq/L) occurring with losartan, especially in the losartan/hydrochlorothiazide combination 6, 7.

Hyponatremia typically develops within 2-207 days of starting losartan (median 24 days), with most cases occurring in elderly patients (mean age 76 years) 7. Symptoms include drowsiness, weakness, and confusion 6.

Clinical Implications:

Avoid Dual RAAS Blockade:

Do not combine losartan with ACE inhibitors or aliskiren, as this significantly increases hyperkalemia risk without additional cardiovascular benefit 3. The VA NEPHRON-D trial demonstrated increased hyperkalemia and acute kidney injury with losartan plus lisinopril compared to monotherapy 3.

Potassium Supplementation:

Long-term potassium supplementation is frequently not needed and may be deleterious when losartan is prescribed 8, 9. ARBs themselves help prevent the hypokalemia caused by loop diuretics 8.

Paradoxical Finding:

Interestingly, in heart failure patients, high-dose losartan (150 mg) actually reduced hypokalemia risk more than low-dose (50 mg), though it did increase hyperkalemia risk slightly 10. Importantly, hypokalemia (≤3.5 mmol/L) was associated with worse outcomes than hyperkalemia in this population 10.

Effect on Other Electrolytes:

Losartan increases uric acid excretion and lowers plasma uric acid levels 11, which may be beneficial. It has minimal direct effect on magnesium or calcium.

Key Monitoring Points:

1. Baseline: Measure potassium, sodium, and creatinine before starting
2. Early phase: Recheck at 1-2 weeks after initiation or dose increase 1, 5
3. Maintenance: Monitor at 1,2,3, and 6 months, then every 6 months 4
4. High-risk patients: More frequent monitoring if eGFR <60 mL/min, diabetes, elderly, or on multiple RAAS inhibitors

The benefits of losartan in reducing cardiovascular morbidity and mortality generally outweigh electrolyte risks when appropriate monitoring is performed 4, 1.